Sr. Principal Scientist Genentech, Inc. South San Francisco, California
In this presentation, we will discuss our LNP screening strategy designed to bolster our RNA discovery programs. The audience will gain insights into the technological advancements of our screening platform, encompassing formulation and characterizations. Additionally, attendees will be presented with our most recent publication in ACS Nano, alongside two other publications from 2022 that showcase our work.
Learning Objectives:
Upon completion, participant will learn the strategy of LNP screening and characterization platform for RNA/Oligonucleotide delivery.
Upon completion, participant will understand the state-of-art structural characterization of LNP.
Upon completion, participant will learn impact of bioactivity on LNP choices.
